Urtikaria nach SARS-CoV-2-Impfung

被引:2
作者
Wang, R. [1 ]
Biedermann, T. [1 ]
Brockow, K. [1 ,2 ]
机构
[1] Tech Univ Munich, Klin & Poliklin Dermatol & Allergol, Klinikum Rechts Isar, Munich, Germany
[2] Tech Univ Munich, Klin & Poliklin Dermatol & Allergol Biederstein, Biedersteiner Str 29, D-80802 Munich, Germany
关键词
SARS-CoV-2; COVID-19; allergy; vaccination; urticaria; allergy tests; URTICARIA; EPIDEMIOLOGY; VACCINE;
D O I
10.5414/ALX02380
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Infections are considered the most common known trigger of acute urticaria. Vaccinations can mimic infections and are also able to trigger urticaria. Methods: This paper describes four exemplary patients with urticaria after SARSCoV-2 vaccination and discusses the occurrence of this adverse event with recent findings from the literature. Results: After SARS-CoV-2 vaccination, both acute (case 1) and chronic spontaneous urticaria (CSU) may occur for the first time (case 2) but a stable well-adjusted CSU may also worsen (case 3) or a pre-existing CSU may recur (case 4). The underlying pathomechanisms are not fully elucidated but activation of the immune system by vaccination seems plausible, similar to infection-triggered urticaria. Subsequent vaccinations are recommended even in the presence of a positive history of urticaria after SARS-CoV-2 vaccination and is often well tolerated; prophylactic administration of antihistamines should be considered. Allergy to vaccine components such as polyethylene glycol (PEG), which can lead to anaphylaxis, is comparatively rare. In cases of urticaria after SARS-CoV-2 vaccination, an accurate history allows risk assessment and provides the indication for further allergy diagnostic workup. Conclusion: Various forms of urticaria are a relatively common cutaneous side effect of SARS-CoV-2 vaccination in cases of pre-existing predisposition. They are not a contraindication to further vaccination. There is no need for further allergy diagnosis in the majority of cases. ©2023 Dustri-Verlag Dr. K. Feistle.
引用
收藏
页码:59 / 64
页数:6
相关论文
共 23 条
[1]   Two Cases of Well Controlled Chronic Spontaneous Urticaria Triggered by the Moderna COVID-19 Vaccine [J].
Alflen, Cylie, III ;
Birch, Katheryn ;
Shilian, Ryan ;
Wu, Shan Shan ;
Hostoffer, Robert, Jr. .
ALLERGY & RHINOLOGY, 2021, 12
[2]   Urticaria: A comprehensive review Epidemiology, diagnosis, and work-up [J].
Antia, Camila ;
Baquerizo, Katherine ;
Korman, Abraham ;
Bernstein, Jonathan A. ;
Alikhan, Ali .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (04) :599-614
[3]   Intolerance to nonsteroidal anti-inflammatory drugs might precede by years the onset of chronic urticaria [J].
Asero, R .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2003, 111 (05) :1095-1098
[4]  
Baden LR, ALLERGY
[5]   Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2 [J].
Blumenthal, Kimberly G. ;
Freeman, Esther E. ;
Saff, Rebecca R. ;
Robinson, Lacey B. ;
Wolfson, Anna R. ;
Foreman, Ruth K. ;
Hashimoto, Dean ;
Banerji, Aleena ;
Li, Lily ;
Anvari, Sara ;
Shenoy, Erica S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (13) :1273-1277
[6]  
Brockow K, ALLERGOLOGIE DRUCK
[7]  
Brockow K, 2021, ALLERGY
[8]   The COVID-19 vaccine and interventional procedures: Exploring the relationship between steroid administration and subsequent vaccine efficacy [J].
Chow, Robert M. ;
Rajput, Kanishka ;
Howie, Benjamin A. ;
Varhabhatla, Narayana .
PAIN PRACTICE, 2021, 21 (08) :966-973
[9]   Comparison of constitutional and dermatologic side effects between COVID-19 and noneCOVID-19 vaccines: Review of a publicly available database of vaccine side effects [J].
Cohen, Stephanie R. ;
Gao, David X. ;
Kahn, Jared S. ;
Rosmarin, David .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 86 (01) :248-249
[10]   Triggers of Exacerbation in Chronic Urticaria and Recurrent Angioedema-Prevalence and Relevance [J].
Grumach, Anete Sevciovic ;
Staubach-Renz, Petra ;
Villa, Ricardo Cardona ;
Diez-Zuluaga, Susana ;
Reese, Imke ;
Lumry, William R. .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (06) :2160-2169